All the news Showing 10 of 61 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Global Liver Institute’s International NASH Day Convenes 80 Partner Organizations and 30 Speakers to Declare Urgency of Combatting Parallel Epidemics of Liver Disease and COVID-19 Global LIver Institute / 15 June 2020 Non-alcoholic fatty liver disease does not raise the risk of COVID-19, gene study shows Keith Alcorn / 26 May 2020 People with a genetic profile that strongly predicts non-alcoholic or metabolic-associated fatty liver disease were not at higher risk of being hospitalised with COVID-19 in the United Kingdom, an analysis of the ... Non-alcoholic fatty liver disease affects a quarter of lean people living with HIV Michael Carter / 13 May 2020 A quarter of people living with HIV with normal body weight have non-alcoholic-fatty liver disease (NAFLD), Italian and Canadian investigators report in Clinical Infectious Diseases. Risk factors were older age, ... Fatty liver disease may increase risk of severe COVID-19 disease Keith Alcorn / 27 April 2020 A preliminary analysis of people admitted to hospital in China with COVID-19 symptoms shows that people with non-alcoholic fatty liver disease (NAFLD) were six times more likely to progress to severe COVID-19 ... HIV-positive people with fatty liver disease are at high risk for fibrosis Liz Highleyman / 23 March 2020 People living with HIV who have non-alcoholic fatty liver disease (NAFLD) often have liver fibrosis and are at risk for fibrosis worsening, researchers reported earlier this month at the Conference ... 'Another swing, another miss' for Gilead as NASH combo flops in phase 2 Fierce Biotech / 16 December 2019 Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Gilead press release / 16 December 2019 Global burden of deaths and liver cancer due to non-alcoholic fatty liver disease growing Keith Alcorn / 11 December 2019 Non-alcoholic fatty liver disease is a growing cause of liver cancer and death in some regions of the world, an analysis of global reporting on liver disease shows. The findings ... New NASH therapies show promise in mid-stage studies Liz Highleyman / 26 November 2019 Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ... People with fatty liver disease struggle to lose weight Liz Highleyman / 25 November 2019 Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can succeed and doing so improves liver health, according to studies ... ← First12345...7Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds